Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial

Read full text Summarise with VIRAT
Authors: Kenshi Suzuki, Morio Matsumoto, Hiroyuki Takamatsu, Hiroshi Kosugi, Tadakazu Kondo, Tomoaki Fujisaki, Thierry T.F. Facon, Sonja Zweegman, Miku Ito, Chika Sakai, Satoshi Kanai, Tomohiko Nakatogawa
+3 more Melissa Rowe, Robin L. Carson, Saad Z. Usmani
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The phase 3 CEPHEUS trial was conducted in 13 countries starting December 11, 2018 in patients with newly diagnosed multiple myeloma (NDMM) who were transplant-ineligible or for whom transplantation was not planned as initial therapy. Bortezomib, lenalidomide, and dexamethasone (VRd) with daratumumab (D-VRd) provided deeper, more durable responses and lowered the risk of disease progression or death compared with VRd. This analysis evaluated the efficacy and safety of D-VRd specifically in the Japanese subpopulation of the CEPHEUS trial (D-VRd: n = 9; VRd: n = 13). At a median follow-up of 59.0 months, the overall minimal residual disease (MRD) negativity rate was 77.8% with D-VRd and 46.2% with VRd (odds ratio: 4.08 [95% confidence interval: 0.60, 27.65]). The complete response or better rate was 88.9% with D-VRd and 76.9% with VRd. Median progression-free survival was not reached in either group, with a hazard ratio of 0.34 favoring D-VRd. The sustained (≥ 12 months) MRD negativity rate was 55.6% with D-VRd and 38.5% with VRd. Efficacy and safety results were similar to those observed in the global CEPHEUS population, supporting the use of D-VRd in Japanese patients with NDMM.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Chronic Lymphocytic Leukemia Research Multiple Sclerosis Research Studies

Publication details

Journal / source
International Journal of Hematology
Volume
124
Issue
1
Pages
104–113
Publication date
27 March 2026
Language
EN